New combo therapy aims to reignite immune attack on resistant cancers
Disease control
Ongoing
This study tests a combination of three treatments—an immune-boosting drug injected into a tumor (IL-2), targeted radiation, and the immunotherapy pembrolizumab—in adults with advanced lung, skin, kidney, or head-and-neck cancers that no longer respond to standard immunotherapy. …
Phase: PHASE1, PHASE2 • Sponsor: Megan Daly, MD • Aim: Disease control
Last updated May 14, 2026 12:05 UTC